Cargando…

Immunotherapy in endometrial cancer: rationale, practice and perspectives

Tumor immunotherapy has attracted more and more attention nowadays, and multiple clinical trials have confirmed its effect in a variety of solid tumors. Immune checkpoint inhibitors (ICIs), cancer vaccines, adoptive cell transfer (ACT), and lymphocyte-promoting cytokines are the main immunotherapy m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Wenyu, Ma, Xinyue, Fischer, Jean Victoria, Sun, Chenggong, Kong, Beihua, Zhang, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207707/ https://www.ncbi.nlm.nih.gov/pubmed/34134781 http://dx.doi.org/10.1186/s40364-021-00301-z

Ejemplares similares

Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives
por: Luo, Wenxin, et al.
Publicado: (2021)

miRNA-576-5p promotes endometrial cancer cell growth and metastasis by targeting ZBTB4
por: Chen, Chen, et al.
Publicado: (2022)

IQGAP3 promotes cancer proliferation and metastasis in high-grade serous ovarian cancer
por: Dongol, Samina, et al.
Publicado: (2020)

The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy
por: Ahmed, Mohamed E., et al.
Publicado: (2020)

Immunotherapy for Peritoneal Metastases from Gastric Cancer: Rationale, Current Practice and Ongoing Trials
por: Ruiz Hispán, Eva, et al.
Publicado: (2021)

Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice
por: Daei Sorkhabi, Amin, et al.
Publicado: (2023)

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
por: Mittica, Gloria, et al.
Publicado: (2017)

MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
por: Sun, Chenggong, et al.
Publicado: (2020)

MiR-501 promotes tumor proliferation and metastasis by targeting HOXD10 in endometrial cancer
por: Sun, Xiaomei, et al.
Publicado: (2021)

Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials
por: Xu, Yang, et al.
Publicado: (2022)

Immunotherapy in endometrial cancer - an evolving therapeutic paradigm
por: Longoria, Teresa C., et al.
Publicado: (2015)

Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia
por: Zhang, Qing, et al.
Publicado: (2017)

Immunotherapy in endometrial cancer: new scenarios on the horizon
por: Di Tucci, Chiara, et al.
Publicado: (2019)

Molecular Basis and Rationale for the Use of Targeted Agents and Immunotherapy in Sinonasal Cancers
por: Esposito, Andrea, et al.
Publicado: (2022)

Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy
por: Zhan, Lei, et al.
Publicado: (2020)

Upregulated MELK Leads to Doxorubicin Chemoresistance and M2 Macrophage Polarization via the miR-34a/JAK2/STAT3 Pathway in Uterine Leiomyosarcoma
por: Zhang, Zhiwei, et al.
Publicado: (2020)

Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
por: Mitsis, Demytra, et al.
Publicado: (2016)

Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective
por: Chen, Shuling, et al.
Publicado: (2022)

Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
por: Rossi, Ernesto, et al.
Publicado: (2019)

Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
por: Tai, David, et al.
Publicado: (2019)

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2019)

The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy
por: Solinas, Cinzia, et al.
Publicado: (2020)

Molecular Mechanisms and Potential Rationale of Immunotherapy in Peritoneal Metastasis of Advanced Gastric Cancer
por: Kang, Donghoon, et al.
Publicado: (2022)

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2020)

Immune biological rationales for the design of combined radio- and immunotherapies
por: Hader, Michael, et al.
Publicado: (2020)

The Perspectives of Fertility Preservation in Women with Endometrial Cancer
por: Knez, Jure, et al.
Publicado: (2021)

Radiomics-based fertility-sparing treatment in endometrial carcinoma: a review
por: Wang, Yuanjian, et al.
Publicado: (2023)

Medical Audit: Rationale and Practicalities
por: Pollock, Alan
Publicado: (1994)

Development of Mucosal Immunity in Children: A Rationale for Sublingual Immunotherapy?
por: Szczawinska-Poplonyk, Aleksandra
Publicado: (2012)

Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review
por: Li, Congcong, et al.
Publicado: (2019)

Mechanistic rationales for combining immunotherapy with radiotherapy
por: Chi, Alexander, et al.
Publicado: (2023)

Current Perspectives in Cancer Immunotherapy
por: Christofi, Theodoulakis, et al.
Publicado: (2019)

Epigenetic Perspective of Immunotherapy for Cancers
por: Keshari, Sunita, et al.
Publicado: (2023)

Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors
por: Lainé, Alexandra, et al.
Publicado: (2023)

Vaginal mucositis related to immunotherapy in endometrial cancer
por: Patel, Jharna M., et al.
Publicado: (2021)

Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose
por: Demoly, Pascal, et al.
Publicado: (2015)

Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges
por: Krishnamoorthy, Mithunah, et al.
Publicado: (2021)

PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2020)

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

A Perspective of Immunotherapy for Prostate Cancer
por: Silvestri, Ida, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_927d2767uuijp1knf9nua7csps